


ΕΓΚΕΦΑΛΟΣ ΚΑΙ ΥΠΕΡΤΑΣΗ: ΠΑΘΟΦΥΣΙΟΛΟΓΙΚΟΙ ΜΗΧΑΝΙΣΜΟΙ

Ο ρόλος της υπέρτασης στην γνωσιακή λειτουργία

# Ρ. Καλαϊτζίδης

ΣΑββΑΤΟ 11 ΝΟΕΜβΡΙΟΥ 2023


# Disclosures



### **Consultant Advisory Board :**Astra Zeneca, MEN, ARINI Boehringer Ingelheim, GSK

**Speaker's Bureau:** ELPEN, Astra Zeneca, MENARINI ,Boehringer Ingelheim, GSK, ASTELLAS

### Ο ρόλος της υπέρτασης στην γνωσιακή λειτουργία



What did the guidelines suggest

Η υπέρταση οδηγεί σε γνωστική δυσλειτουργία


Η υπέρταση οδηγεί σε αρτηριακή σκληρία που προκαλεί γνωστική δυσλειτουργία


Pathophysiologic mechanisms

Ο έλεγχος της ΑΠ βελτιώνει την γνωστική δυσλειτουργία?


Συμπεράσματα


### Risks leading to death in perspective






### Increased blood pressure (red arrow) is the second leading risk attributed to 17.8% of global deaths.





Global, deaths

Clin Hypertens (Greenwich). 2015:1–3



# Cognitive impairment is comparatively less considered to be an adverse effect of hypertension



## What did the guidelines suggest?

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

> WRITING COMMITTEE MEMBERS Paul K. Whelton, MB, MD, MSc, FAHA, Chair Robert M. Carev, MD, FAHA, Vice Chair



When the rate of cognitive decline (not dementia) has been a trial outcome **7 clinical trials** of BP-lowering therapy have been completed, and **2 of these have shown benefit** .S11.3-4–S11.3-6,S11.3-19–S11.3-22

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

> WRITING COMMITTEE MEMBERS Paul K. Whelton, MB, MD, MSc, FAHA, Chair Robert M, Carev, MD, FAHA, Vice Chair



Hypertension is also the primary risk factor **for small-vessel ischemic disease and cortical white matter abnormalities**.S11.3-12–

**Vascular disease** and its risk factors are implicated in a large proportion of patients with **dementia**, including those with **Alzheimer's dementi** a.S11.3-9–S11.3-

Dementia is a leading cause of mortality and placement into nursing homes and assisted living facilities, affecting >46 million individuals globally and 5 million persons in the United States, a number that is expected to **double** by 2050.S11.3-7

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

> WRITING COMMITTEE MEMBERS Paul K. Whelton, MB, MD, MSc, FAHA, Chair Robert M. Carev, MD, FAHA, Vice Chair

Most **observational studies** have suggested that better control of SBP **may reduce** Alzheimer's disease and other dementias



The evidence is stronger for BP lowering in **middle age** than in older adults.

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

> WRITING COMMITTEE MEMBERS Paul K. Whelton, MB, MD, MSc, FAHA, Chair Robert M. Carev, MD, FAHA, Vice Chair



### **11.3. Cognitive Decline and Dementia**

Recommendation for Prevention of Cognitive Decline and Dementia

References that support the recommendation are summarized in Online Data Supplement 56.

COR	LOE	Recommendation	
lla	B-R	<ol> <li>In adults with hypertension, BP lowering is reasonable to prevent cognitive decline and dementia.<sup>S11.3-1-S11.3-6</sup></li> </ol>	

2023 ESH Guidelines for the management of arterial hypertension



### Hypertension in **midlife** predicts

 Cognitive decline
 Alzheimer's disease
 Vascular dementia in older patients [1267,1268]. 2023 ESH Guidelines for the management of arterial hypertension




The effects of antihypertensive drug class in late life to prevent cognitive impairment, however, remain unclear.

Medication class may **be less relevant** if the SBP is not adequately controlled

# 2023 ESH Guidelines for the management of arterial hypertension



Several studies have shown that strict BP control, i.e. SBP <130 mmHg, reduces the progression of cerebral white matter lesions and the decrease in global cognitive performance [470,1275,1276].



# Impact of Hypertension on Cognition

# Cognitive domains and disorders associated with hypertension



Characteristic cognitive dysfunction domains

Greater impact on frontal lobe executive function

Goal formation

Abstract thinking

Initiating

Planning

Organizing

Sequencing

Performed better on memory tests

Impairments in recall

Relatively intact recognition

Benefit from cues

Mild forgetfulness

Cognitive disorders (the strength of the association is in the order listed)

Vascular dementia

Alzheimer disease

Dementia with Lewy body



J Yeungnam Med Sci 2023;40(3):225-232


### Impact of Hypertension on Cognition



**Cognitive decline** (worsening of cognitive function over years to decades, steeper than expected because of age alone) [Γνωστική εξασθένηση ]

Mild cognitive impairment (MCI; reduced function in memory, thinking, and other cognitive domains but not impacting daily fun tioning) ['Ηπια γνωστική εξασθένηση ]

> Dementia (impairments in cognition, including memory and other cognitive domains, but with adverse impacts on daily functioning) [Άνοια]



# Hypertension a risk factor for adverse cognitive outcomes

### Hypertension is clearly associated with






Steeper cognitive decline [απότομη ]

Poor cognitive performance [Κακή γνωστική απόδοση]

Incident mild cognitive impairment


Dementia

J Yeungnam Med Sci 2023;40(3):225-232



# **CLINICAL TRIALS**

### Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial



In elderly patients with isolated systolic hypertension, active treatment starting with the dihydropyridine calcium-channel blocker nitrendipine halved the rate of dementia from 7.7 to 3.8 cases per 1000 patient-years.

# Figure 3: Changes in MMSE score associated with mean decrease in systolic and diastolic blood pressure in placebo and active treatment groups

Association sizes adjusted for sex, age, educational level, previous cardiovascular complications, antihypertensive treatment before enrolment, smoking, and alcohol consumption at randomisation.

### In elderly people with isolated systolic hypertension, antihypertensive treatment was associated with a lower incidence of dementia.

Lancet 1998; 352: 1347-5

# Cognitive decline in individuals with high blood pressure: A longitudinal study in the elderly

Tzourio, Christophe MD, PhD; Dufouil, Carole PhD; Ducimetiere, Pierre PhD; Alperovitch, Annick MD, MSc; for the EVA Study Group

		Cognitive decline <sup>†</sup>		
Blood pressure status at baseline*	n	%	Adjusted odds ratio‡ (95% CI)	
Men				
Normal blood pressure	393	7.6	1§	
High blood pressure	80	18.8	2.6 (1.2-5.7)	
Women				
Normal blood pressure	623	7.2	1§	
High blood pressure	53	15.2	2.9 (1.3-7.0)	
Both sexes				
Normal blood pressure	1,016	7.4	1§	
High blood pressure	133	17.3	2.8(1.6-5.0)	

\* High blood pressure was defined as systolic BP  $\geq$  160 mm Hg

The risk of cognitive decliine was 4.3 (95% CI, 2.1 to 8.8) in those without antihypertensive therapy and 1.9 (95% CI, 0.8 to 4.4) in those being treated

NeurologyIssue: Volume 53(9), 10 December 1999, pp 1948-1952

## Antihypertensive medication use and risk of cognitive impairment


The Honolulu-Asia Aging Study

# Επίπεδα Αρτηριακής Πίεσης



Analyses from the Honolulu Asia Aging Study (HAAS) have estimated that 27% of dementia cases may be attributed to midlife SBP >-120 mm Hg among inadequately treated men

### Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia



Among ambulatory adults with hypertension, treating to a systolic blood pressure goal of less than 120 mm Hg compared with a goal of less than 140 mm Hg **DID NOT RESULT IN A** SIGNIFICANT **REDUCTION IN THE RISK OF PROBABLE DEMENTIA**, Because of early study termination and fewer than expected cases of dementia, the study may have been underpowered for this end point.

Median follow-up time was **5.14 years** (interquartile range, 3.91-6.00) for the intensive treatment group and **5.07 years** (interquartile range, 3.87-5.98) for the standard treatment group. For group comparison of incidence, hazard ratio, 0.83; 95% CI, 0.67-1.04; *P*=.10

JAMA. 2019 Feb 12; 321(6): 553-561

### Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia

Outcomes	Treatment Group Intensive		Standard		Hazard Ratio	P Value
	No. With Outcome/Person- Years	Cases per 1000 Person-	No. With Outcome/Person- Years	Cases per 1000 Person-	(95% CI) <sup>a</sup>	
Probable dementia	140/20 560	Years 7.2	176/20279	Years 8.6	0.83	.10
Probable dementia	149/20 569	7.2	176/20378	0.0	0.85 (0.67- 1.04)	.10
Mild cognitive impairment <sup>b</sup>	287/19690	14.6	353/19281	18.3	0.81 (0.69- 0.95)	.007
Composite of mild cognitive impairment or probable dementia	402/19873	20.2	469/19 488	24.1	0.85 (0.74- 0.97)	.01

Incidence of Probable Dementia and Mild Cognitive Impairment by Treatment Group

ledian follow-up time was 5.14 years (interquartile range, 3.91-6.00) for the intensive treatment roup and 5.07 years (interquartile range, 3.87-5.98) for the standard treatment group. or group comparison of incidence, hazard ratio, 0.83; 95% CI, 0.67-1.04; *P*=.10

JAMA. 2019 Feb 12; 321(6): 553-561



# Have been suggested a U-shaped relationship between BP and cognition ?



# Isolated studies of older adults

RESEARCH ARTICLES | DECEMBER 15 2000

### Blood Pressure and Risk of Dementia: Results from the Rotterdam Study and the Gothenburg H-70 Study

In an analysis including data from the **Rotterdam study and the Göteborg H-70 study**, hypertension in old age appeared protective:

Elderly adults had an inverse association between BP and dementia, with a reduced relative risk for dementia of 0.93 (95% CI, 0.88–0.99) per 10 mmHg higher SBP

This association was confined to subjects who used anthypertensive medication.

Dement Geriatr Cogn Disord. 2001;12:33–39. doi: 10.1159/000051233

The Effect of Age on the Association Between Blood Pressure and Cognitive Function Later in Life

High BP was associated with greater risk of cognitive impairment in persons younger than 75 but with better cognitive function in older persons




Lower BP might lead to hypoperfusion and thus *worse* cognitive outcomes in older persons

https://doi.org/10.1111/j.1532-5415.2009.02264.x

# Ο ρόλος της Διαστολικής ΑΠ στην γνωστική λειτουργία

#### Diastolic Blood Pressure and Intensive Blood Pressure Control on Cognitive Outcomes: Insights From the SPRINT MIND Trial

Chao Jiang ( , Sitong Li ( , Yufeng Wang, Yiwei Lai, Yu Bai ( , Manlin Zhao, Liu He, Yu Kong, Xueyuan Guo, Songnan Li, Nian Liu, Chenxi Jiang, Ribo Tang, Caihua Sang, Deyong Long, Xin Du ( , Jianzeng Dong ( , Craig S. Anderson ( , and Changsheng Ma (




Incidence rates of cognitive outcomes by randomized systolic blood pressure (SBP) intervention and baseline diastolic blood pressure (DBP) quartile.

**Conclusions:**I ntensive BP control **DID NOT APPEAR TO HAVE** a detrimental effect on cognitive outcomes and cerebral perfusion in patients with low baseline DBP.

Hypertension Volume 80, Issue 3, March 2023; Pages 580-589

### Diastolic Blood Pressure and Intensive Blood Pressure Control on Cognitive Outcomes: Insights From the SPRINT MIND Trial

Chao Jiang ( , Sitong Li ( , Yufeng Wang, Yiwei Lai, Yu Bai ( , Manlin Zhao, Liu He, Yu Kong, Xueyuan Guo, Songnan Li, Nian Liu, Chenxi Jiang, Ribo Tang, Caihua Sang, Deyong Long, Xin Du ( , Jianzeng Dong ( , Craig S. Anderson ( , and Changsheng Ma (



In this **post hoc analysis** of the SPRINT MIND study, patients with lower DBP had a higher incidence of dementia or MCL Nevertheless, intensive BP control did not appear to have a detrimental effect on cognitive function and cerebral perfusion. Low DBP level should not be an obstacle to intensive BP control from the perspective of brain health.

Effect of systolic blood pressure intervention on annualized CHANGE IN CEREBRAL BLOOD flow by baseline diastolic blood pressure (DBP) quartile.

HypertensionVolume 80, Issue 3, March 2023; Pages 580-589

# Age-Dependent Risk Midlife Versus Late Life



Hypertension's impact on late-life cognitive outcomes appears the greatest when considered in middle age

**Midlife Versus Late Life** 

### Midlife hypertension and 20-year cognitive change: The Atherosclerosis Risk in Communities Neurocognitive Study


Additional adjusted 20-year cognitive change for the association of visit 2 (1990–1992) with recommended treatmen t

	Cognitive Change (95% CI)		
	HTN Treatment Not Indicated <sup>a</sup>	HTN Treatment Indicated <sup>b</sup>	
All Participants <sup>C</sup>			
	(n=8,165)	(n=5,311)	
Global z score	0 (reference)	-0.044 (-0.085, -0.003)	
DWRT z score	0 (reference)	-0.008 (-0.074, 0.058)	
DSST z score	0 (reference)	-0.064 (-0.093, -0.035)	
WFT z score	0 (reference)	-0.042 (-0.079, -0.005)	
DWRT raw score, No. of words	0 (reference)	-0.012 (-0.112, 0.088)	
DSST raw score, No. of symbols	0 (reference)	-0.909 (-1.319, -0.498)	
WFT raw score, No. of words	0 (reference)	-0.520 (-0.982, -0.058)	

Midlife hypertension and elevated midlife **BUT NOT LATE-LIFE SYSTOLIC BP** was associated with more cognitive decline during the 20 years of the study. Greater decline is found with higher midlife BP in whites than in African Americans

JAMA Neurol. 2014 October 1; 71(10): 1218–1227

BMJ Open Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case-control study using European electronic health records



Mid-life SBP is a risk factor for dementia incidence 10–20 years later



LOWER SBP IN CASES AT THE TIME OF DIAGNOSIS

BMI, SBP and total cholesterol levels were lower overall in cases with dementia than controls and the difference was most marked closest to the point of diagnosis.

. BMJ Open 2020;10:e038753. doi:10.1136/

Studies using IMAGING surrogates for cognitive or dementia status



# Also support the importance **of midlife** hypertension

### High Blood Pressure and Cerebral White Matter Lesion Progression in the General Population

Benjamin F.J. Verhaaren, Meike W. Vernooij, Renske de Boer, Albert Hofman, Wiro J. Niessen, Aad van der Lugt, M. Arfan Ikram





Figure 1. Schematic overview of the study design. BP indicates blood pressure; and WML, white matter lesion.

High blood pressure to precede **cerebral white matter lesions** and implies that hypertension treatment could reduce WML progression in the general population.

Hypertension. 2013;61:1354-1359

### High Blood Pressure and Cerebral White Matter Lesion Progression in the General Population

Benjamin F.J. Verhaaren, Meike W. Vernooij, Renske de Boer, Albert Hofman, Wiro J. Niessen, Aad van der Lugt, M. Arfan Ikram



Hypertension treatment and white matter lesion (WML) progression.

High blood pressure to precede cerebral white matter lesions and implies that hypertension treatment could reduce WML progression in the general population.

### Hypertension. 2013;61:1354-1359

Association of midlife blood pressure to late-life cognitive decline and brain morphology

- In the National Heart, Lung, and Blood Institute Twin Study,
  - midlife SBP was associated
  - with not only more white matter hyperintensities in later life but also
- SMALLER BRAIN PARENCHYMAL VOLUMES

Swan GE, DeCarli C, Miller BL, Reed T, Wolf PA, Jack LM, Carmelli D. Association of midlife blood pressure to late-life cognitive decline and brain morphology. *Neurology*. 1998;51:986–99

#### Hypertension Is Related to Cognitive Impairment A 20-Year Follow-up of 999 Men

Lena Kilander, Håkan Nyman, Merike Boberg, Lennart Hansson, Hans Lithell

	Cognitive	Function		Logistic Regression		
Characteristic	Normal (n=743)	Low (n=186)	<b>P</b> <sup>1</sup>	OR (95% CI)	<b>P</b> <sup>2</sup>	
24-h DBP, mm Hg	76 (8)	78 (8)	.0002	1.45 (1.20-1.75)	.0001	
fP-Glucose, mmol/L	5.7 (1.4)	6.0 (1.8)	.034	1.13 (0.94–1.37)	.188	
fP-Insulin, mU/L	12.7 (8.2)	13.3 (9.2)	.984	0.87 (0.69-1.09)	.223	
M/I	5.2 (2.5)	4.8 (2.6)	.155	1.00 (0.77-1.29)	.983	
fS-Triglycerides, mmol/L	1.39 (0.71)	1.57 (1.04)	.271	0.99 (0.79-1.23)	.911	
BMI, kg/m <sup>2</sup>	26.1 (3.2)	26.9 (3.9)	.089	1.12 (0.89-1.41)	.346	
HDL cholesterol, mmol/L	1.30 (0.34)	1.25 (0.37)	.232	0.90 (0.72-1.13)	.349	
Antihypertensive treatment, %	32.6	33.3	.775	0.64 (0.42-0.98)	.0418	
Age, y	72.3	72.8		1.35 (1.14-1.58)	.0003	
Education, L/M/H	46/35/19%	81/15/4%		0.42 (0.27-0.65)	.0001	
Occupation, L/M/H	35/42/23%	66/30/4%		0.57 (0.39-0.83)	.0038	

#### TABLE 3. Determinants of Low Cognitive Performance: Cross-sectional Data at Age 70 Years

InUppsala, Sweden, using ambulatory BP monitoring, nondipping circadian BP

patterns and persistently high 24-hour BP (at70 years of age)

was associated with worse cognitive performance

Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertensionis related to cognitive impairment: a 20-year follow-up of 999 men.*Hypertension*. 1998;31:780–786.

### Pulse pressure is associated with early brain atrophy and cognitive decline: modifying effects of APOE4

Regression results for baseline pulse pressure predicting cognition at 5-7 year follow-up and annualized change in cognition, as well as interactions with the APOE-e4 carrier status and blood pressure group.

A Time 2 Performance	Pulse Pressure (mm Hg) Main Effects		Blood pressure group <sup>*</sup> Interaction	APOE-e4 status Interaction	
	Beta (SE)	Р	Р	Р	
LM-delayed	-0.0018 (0.013)	0.89	0.08	0.48	
VR-delayed	-0.018 (0.011)	0.10	0.74	0.09	
Similarities	0.0017 (0.011)	0.88	0.60	0.16	
Trails A ""	-0.0017 (0.0012)	0.17	0.68	0.22	
Trails B-A	-0.0015 (0.00068)	0.02	0.25	0.66	
BNT **	0.0021 (0.0022)	0.34	0.36	0.42	
HVOT **	-0.0021 (0.0018)	0.25	0.63	0.26	
В					
Time 2-1 Performance	Beta (SE)	Р	Р	Р	
LM-delayed	-0.00085 (0.0020)	0.67	0.11	0.49	
VR-delayed	-0.00045 (0.0017)	0.79	0.82	0.78	
Similarities	-0.0010 (0.0018)	0.57	0.43	0.18	
Trails A	-0.000014 (0.00011)	0.89	0.69	0.68	
Trails B-A	-0.00098 (0.00045)	0.03	0.65	0.30	
DATE	0.000020 (0.00001)	0.05	0.24	0.08	

**PULSE PRESSURE** was associated with cognitive decline among apolipoprotein E)-ε4 carriers in the Framingham Offspring Study.

. Alzheimer Dis Assoc Disord. 2016;30:210–215.

## Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study

Table 2| Cognitive function in thirds of visit-to-visit blood pressure variability. Values are means (standard errors) unless stated otherwise

Variables	Third of	P value			
	Low (n=1820)	Middle (n=1821)	High (n=1820)	_	
Systolic blood pressure					
Range of SD (mm Hg)	0.7-12.2	12.3-16.2	16.3-64.4	_	
Stroop test score (seconds)	68.46 (0.79)	68.75 (0.79)	71.54 (0.82)	<0.001	
Letter-digit coding test score (digits coded)	22.40 (0.19)	21.82 (0.19)	21.24 (0.19)	<0.001	
Picture-word learning test (pictures remembered):					
Immediate recall score	9.37 (0.05)	9.28 (0.05)	9.10 (0.05)	<0.001	
Delayed recall score	10.00 (0.07)	9.89 (0.07)	9.70 (0.08)	0.001	
Diastolic blood pressure					
Range of SD (mm Hg)	0-6.5	6.6-8.5	8.6-33.1	_	
Stroop test score (seconds)	68.28 (0.79)	68.89 (0.79)	71.34 (0.80)	<0.001	
Letter-digit coding test score (digits coded)	22.35 (0.19)	21.93 (0.19)	21.27 (0.19)	<0.001	
Picture-word learning test (pictures remembered):					
Immediate recall score	9.41 (0.05)	9.22 (0.05)	9.13 (0.05)	<0.001	
Delayed recall score	10.01 (0.07)	9.88 (0.07)	9.74 (0.07)	0.001	

- BP variability has also been described in several studies as an important risk factor for reduced cognitive function.
  - Higher visit-to-visit variability in blood pressure independent of average blood pressure was associated with impaired cognitive function in old age.

*BMJ*. 2013;347:f4600. doi: 10.1136/bmj.f4600

## Patients with HYPERTENSION AND CKD

#### **Risk factors for cognitive dysfunction in CKD and hypertensive subjects**

Rigas G. Kalaitzidis · Despina Karasavvidou · Athina Tatsioni · Olga Balafa · Kosmas Pappas · Giorgos Spanos · Sigkliti-Henrietta Pelidou · Kostas C. Siamopoulos

Cognitive tests	Factor	OR (95 % CI)	р
MMSE	Stages	2.46 (1.81-3.34)	< 0.001
	Age (years)	1.06 (1.02-1.09)	0.001
	DM	4.27 (1.88-9.75)	0.001
	РТН	1.01 (1.00-1.01)	0.010
Clock test	Stages	1.92 (1.23-2.99)	0.004
	Age (years)	1.07 (1.03-1.11)	0.001
	DM	4.48 (1.86-10.83)	0.001
	РТН	1.92 (1.23-2.99)	0.004
IADL	Stages	1.75 (1.26-2.45)	0.001
	Age (years)	1.11 (1.05-1.16)	0.000
	DM	7.64 (3.12-18.73)	0.000
l	UTPR	1.00 (1.00-1.00)	0.047

 Table 3 Multivariate analysis of non-dialysis population

Int Urol Nephrol 2013, DOI 10.1007/s11255-013-0450-y

Ο ρόλος της υπέρτασης στην γνωσιακή λειτουργία

What did the guidelines suggest

Η υπέρταση οδηγεί σε γνωστική δυσλειτουργία

Η υπέρταση οδηγεί σε αρτηριακή σκληρία που προκαλεί γνωστική δυσλειτουργία


Pathophysiologic mechanisms

Ο έλεγχος της ΑΠ βελτιώνει την γνωστική δυσλειτουργία?

Συμπεράσματα

#### ORIGINAL CONTRIBUTIONS

Relationship Between Arterial Stiffness and Cognitive Function in Elderly PWV (m/sec)




#### Relationship between PWV and cognitive status (normal cognitive function


Our results showed a relationship between arterial stiffness and cognitive impairment, suggesting that functional changes of the arterial system could be involved in the onset of dementia (VaD or AD types)

Relationship between arterial stiffness and cognitive function in outpatients with dementia and mild cognitive impairment compared with community residents without dementia

Journal of Geriatric Cardiology



The baPWV values of Controls, MCI, AD, VaD and MIX patients. AD: Alzheimer's disease; MCI: mild cognitive impairment; MIX: mixed dementia; VaD: vascular dementia Relationship between arterial stiffness and cognitive function in outpatients with dementia and mild cognitive impairment compared with community residents without dementia



#### the baPWV value to predict the presence of dementia.

The ORs are expressed as higher baPWV value (A) and per 1 m/s increase (B) in baPWV after adjustment for age gender, diabetes mellitus, hyperlipidemia, hypertension and smoking status

## Albuminuria as a marker of arterial stiffness in chronic kidney disease patients

Rigas G Kalaitzidis, Despina P Karasavvidou, Athina Tatsioni, Kosmas Pappas, Giorgos Katatsis, Angelos Liontos, Moses S Elisaf

 Table 4 Multivariate linear regression analysis of the parameters associated with the absolute values of pulse wave velocity


Covariates	β	t	β <b>(95%Cl)</b>	<i>P</i> value
UAlb	1.038	2.638	0.257-1.820	< 0.010
pSBP	0.028	2.149	0.002-0.053	< 0.034
Ht	0.171	3.319	0.069-0.273	< 0.001

pSBP: Peripheral systolic blood pressure; Ht: Haematocrit.

World J Nephrol 205 July 6; 4(3): 00-00

## Arterial damage and cognitive decline in chronic kidney disease patients

Despina Karasavvidou MD, PhD<sup>1</sup> | Pierre Boutouyrie MD<sup>2</sup> | Rigas Kalaitzidis MD<sup>3</sup> | Hakim Kettab MD<sup>2</sup> | Kosmas Pappas MD<sup>3</sup> | Dimitrios Stagikas MD<sup>3</sup> | Nikolaos Antonakis PhD<sup>1</sup> | Dimitrios Tsalikakis PhD<sup>2</sup> | Moses Elisaf MD<sup>3</sup> | Stephane Laurent MD<sup>4</sup>



**FIGURE 2** 3D plot showing the interaction of IADL, GFR-MDRD, and age. IADL, Instrumental activity of daily living; GFR-MDRD, glomerular filtration rate -modification of diet in renal disease

In CKD patients cognitive function was profoundly altered in parallel with the severity of CKD. High levels **of arterial stiffness indices**, either directly measured as cf-PWV or indirectly estimated as **aortic PP**, were correlated with MMSE, an index of cognitive decline.

J Clin Hypertens. 2018;1–9

## Αρρύθμιστη Υπέρταση

## Αρτηριακή σκληρία


## γνωστική λειτουργία

### Arterial Stiffness, Cognitive Dysfunction, and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?

Rigas G Kalaitzidis<sup>1,\*</sup>, Thalia Panagiotopoulou<sup>2</sup>, Dimitrios Stagikas<sup>2</sup>, Kosmas Pappas<sup>2</sup>, Olga Balafa<sup>1</sup> and Moses S Elisaf<sup>2</sup>

6 Current Vascular Pharmacology, 2019, Vol. 17, No. 00

Kalaitzidis et al.




Relationship between uncontrolled hypertension, arterial stiffness, cognitive dysfunction and noncompliance with treatment

#### RESEARCH ARTICLE

#### Adherence to Treatment, Arterial Stiffness and Cognitive Function in Irbesartan-Treated Newly Diagnosed Hypertensive Patients


Rigas G. Kalaitzidis<sup>1,\*</sup>, Olga Balafa<sup>1</sup>, Evangelia Dounousi<sup>1</sup>, Dimitrios Stagikas<sup>1</sup> and Vasilios Tsimihodimos<sup>1</sup>



## Δx MMSE and Adherence

Fig. (1). MMSE and Adherence. MMSE test: Mini Mental State Examination test,  $\Delta x$ : Change in MMSE test before and after the treatment with irbesartan.

Current Vascular Pharmacology, 2021, Vol. 19, No. 00 5



## P&THOPHÝSIOLOGIC MECH&NISMS

### Small vessel disease of the brain

The small vessels of the brain are unique as their cells receive continuous high-volume flow throughout systole and diastole against VERY LOW VASCULAR RESISTANCE.


Given the particular anatomy and physiology of small vessel circulation, brain tissue are susceptible to the microvascular insults in response to aging and exposure to vascular risk factors

## Are more prone to developing what is commonly referred as SVD


Stroke. (2009) 40:e322-30. doi: 10.1161/STROKEAHA.108.54 2266

Cardiol Res Pract 2011: 306189, 2011)]

### CEREBROVASCULAR AUTOREGULATION AND HYPERTENSION





Putative mechanisms of neurovascular dysfunction in slow-pressor Ang II ,hypertension, BPH mice and deoxycorticosterone acetate+salt hypertension.




Circulating or brain Ang II reaches AT1R (angiotensin type-1 receptor) in perivascular macrophage (PVM)wherein it activates NOX2 leading the vascular oxidative stress and neurovascular dysfunction. AT1R and Nox2 are also present in other vascular cells, butthey do not seem to play a primary role in these hypertension models.

#### Potential mechanisms of white matter (WM) damage by hypertension






## Cerebrovascular anatomy and segmental pathology induced by hypertension




The predominant pathology caused by hypertension in the different segment of the cerebrovascular tree is indicated. Because of its precarious blood supply **from terminal arterioles** particularly vulnerable to hypertensive damage, the subcortical WM is highly likely to be harmed by hypoxia-ischemia. ICA indicates internal carotid artery; and MCA, middle cerebral artery.




J Yeungnam Med Sci 2023;40(3):225-232


## Potential mechanisms underlying the relationship between hypertension and **Alzheimer disease**




## Vascular hypothesis




## Amyloid hypothesis;




## H) Mitochondrial hypothesis.



#### Neuroinflammation hypothesis;







## Synaptic dysfunction hypothesis;

## E)


↓ Number of synapses ↓ Dendritic arborization




## Cholinergic hypothesis;



### Glutaminergic hypothesis;






# Ο έλεγχος της ΑΠ βελτιώνει την γνωστική δυσλειτουργία?

#### Effects of Antihypertensive Drugs on Cognitive Function in Elderly Patients with Hypertension: A Review

Wei Yang\*, Hongyu Luo, Yixin Ma, Sicong Si, Huan Zhao



The underlying mechanism of cognitive impairment caused by hypertension in the elderly

Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack (Review)

Zonneveld TP, Richard E, Vergouwen MDI, Nederkoorn PJ, de Haan RJ, Roos YBWEM, Kruyt ND

			$\bigcap$			
Death by any cause	35,110 (8 RCTs)	⊕⊕⊕⊝ Moderate <sup>a</sup>		RR 0.98 (0.91 to 1.05)	Study population	
	(0 NC 13)	Moderates		(0.51 (0 1.05)	79 per 1000	2 fewer per 1000 (7 fewer to 4 more)
Dementia	6671 (2 RCTs)	⊕⊕⊕⊕ High		RR 0.88 (0.73 to 1.06)	Study population	
	(2 11013)	nigii		(0.75 (0 1.00)	67 per 1000	8 fewer per 1000 (18 fewer to 4 more)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and						

its 95% CI).

BPLDs: blood pressure-lowering drugs; CI: confidence interval; HR: hazard ratio; RCT: randomised controlled trial; RR: risk ratio.

*Cochrane Database of Systematic Reviews* 2018, Issue 7. Art. No.: CD007858

#### **Reducing the Risk of Dementia** Efficacy of Long-Term Treatment of Hypertension

Rita Peila, PhD; Lon R. White, MD, MPH; Kamal Masaki, MD; Helen Petrovitch, MD; Lenore J. Launer, PhD

#### **Duration of Treatment With Antihypertensive**

**Medications and Yearly Cognitive Function** 

	м	idlife Hyp Treatmen			
	Never	0-5	5–12	>12	Normotensives
No.	121	171	138	342	414
Initial CASI score	83.05	82.86	82.56	83.03	81.58
CASI change/y	-1.46*‡	-1.22	-1.14†	-1.08	-1.01†

The untreated hypertensive group is the reference group for the analysis. \**P* value <0.01 compared to a slope=0; †*P* value <0.05 compared to the reference group. The analysis was adjusted for age and age squared at baseline, education, *APOE*  $\varepsilon$ 4 status, midlife (mean of exam 1, 2 and 3) and late-life (exam 4) blood pressure and smoking status.

#### The longer the duration of antihypertensive medication use, the significantly lower the risk for dementia

Results suggest that in hypertensive men, the duration of the antihypertensive treatment is associated with a reduced risk for dementia and cognitive decline

#### Stroke. 2006;37:1165-1170.

#### Original Investigation | Geriatrics Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life An Individual Participant Data Meta-Analysis

HR (95% CI) P for interaction Analysis Main analysis Treated HTN 1.13 (0.99-1.28) Untreated HTN 1.42 (1.15-1.76) Fully adjusted Treated HTN 1.04 (0.88-1.22) 1.37 (1.04-1.81) Untreated HTM >5 y follow-up 1.14 (0.97-1.35) Treated HTN 1.30 (0.97-1.76) Untreated HTN Age, y 60 Treated HTN 1.45 (1.07-1.96) Untreated HTN 1.51 (0.90-2.53) 70 1.24 (1.05-1.46) Treated HTN Untreated HTN 1.44 (1.09-1.91) P for treated = .08 P for untreated = .76 80 1.06 (0.92-1.22) Treated HTN Untreated HTN 1.38 (1.09-1.75) 90 0.91 (0.69-1.19) Treated HTN Untreated HTN 1.32 (0.84-2.06) Sex Male Treated HTN 1.21 (0.99-1.48) 1.53 (1.08-2.15) Untreated HTN Female P for treated = .36 Treated HTN 1.08 (0.92-1.26) P for untreated=.59 Untreated HTN 1.36 (1.04-1.77) Race White 1.13 (0.98-1.31) Treated HTN P for treated = .82 Untreated HTN 1.40 (1.10-1.80) Asian 1.18 (0.87-1.59) P for untreated = .98 Treated HTN Untreated HTN 1.40 (0.84-2.32) P for treated=.39 Black Treated HTN 0.83 (0.42-1.64) P for untreated = .87 Untreated HTN 1.51 (0.62-3.71) 0.5 3 0.2 0.3 2 HR (95% CI)

Association of Hypertension (HTN) and Antihypertensive Status With the Risk of All-Cause Dementia


This individual patient data meta-analysis of longitudinal cohort studies found **that antihypertensive use was associated with decreased dementia risk** compared with individuals with untreated hypertension through all ages in late life. Individuals with treated hypertension had no increased risk of dementia compared with healthy controls.

#### JAMA Network Open. 2023;6(9):e2333353

Original Investigation | Geriatrics Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life

An Individual Participant Data Meta-Analysis

The Associations of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure



A SINGLE MEASURE OF SBP OR DBP AT BASELINE HAD NO SIGNIFICANT ASSOCIATION with latelife dementia risk, and, corroborating extant hypertension guidelines,46 it seems that more than 1 measure is needed to inform treatment

JAMA Network Open. 2023;6(9):e2333353

Original Investigation | Geriatrics Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life An Individual Participant Data Meta-Analysis

Dementia risk reduction may be 1 of the multiple goals of antihypertensive treatment in late-life (eg, prevention of ischemic heart disease, chronic kidney disease).

This individual patient data meta-analysis of longitudinal cohort studies found that antihypertensive use was associated with decreased dementia risk compared with individuals with untreated hypertension through all ages in late life. Individuals with treated hypertension had no increased risk of dementia compared with healthy controls.

JAMA Network Open. 2023;6(9):e2333353

